Shannon Campbell
Vermogen: 19 680 $ op 31-05-2026
Vermogen: 19 680 $ op 31-05-2026
Shannon Campbell is currently Director at Zentalis Pharmaceuticals, Inc. since 2026 and Independent Director at Black Diamond Therapeutics, Inc. since 2024.
Formerly, Ms. Campbell was Chief Commercial Officer & Executive VP at Merus NV from 2022 to 2026 and Vice President & General Manager-Oncology at Bayer HealthCare Pharmaceuticals, Inc. from 2005 to 2017.
Education includes undergraduate studies at Ithaca College.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 27-04-2026 | 8.865 ( 0,02% ) | 19 680 $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| BLACK DIAMOND THERAPEUTICS, INC. | Directeur/Bestuurslid | 10-04-2024 |
| ZENTALIS PHARMACEUTICALS, INC. | Directeur/Bestuurslid | 22-05-2026 |
| Bedrijven | Functie | Einde |
|---|---|---|
| MERUS N.V. | Corporate Officer/Principal | 01-01-2026 |
Bayer HealthCare Pharmaceuticals, Inc.
Bayer HealthCare Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical drugs | Corporate Officer/Principal | 01-01-2017 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 5 |
|---|---|
Ithaca College
Ithaca College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bayer HealthCare Pharmaceuticals, Inc.
Bayer HealthCare Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical drugs | Health Technology |
Merus NV
Merus NV BiotechnologyHealth Technology Discovers and develops therapeutics for cancer treatment | Health Technology |
Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops precision medicines for cancer | Health Technology |
Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops clinical therapeutics for targeting fundamental cancer pathways | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau